KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
University of Vienna · Czech Academy of Sciences, Institute of Inorganic Chemistry · +3 more institutions
Abstract
The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (Hartinger et al., J. Inorg. Biochem. 2006, 100, 891-904), the experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction. The results of the early clinical development of KP1019 are summarized in which five out of six evaluated patients experienced disease stabilization with no severe side effects.
Citation impact
- FWCI
- 14.85
- Percentile
- 100%
- References
- 85
Authors
9- CGChristian G. HartingerCorresponding
University of Vienna, Czech Academy of Sciences, Institute of Inorganic Chemistry, École Polytechnique Fédérale de Lausanne
- MAMichael A. Jakupec
University of Vienna, Czech Academy of Sciences, Institute of Inorganic Chemistry
- SZStefanie Zorbas‐Seifried
University of Vienna, Czech Academy of Sciences, Institute of Inorganic Chemistry, Max Planck Institute of Biochemistry
- MGMichael Groessl
University of Vienna, Czech Academy of Sciences, Institute of Inorganic Chemistry
- AEAlexander Egger
University of Vienna, Czech Academy of Sciences, Institute of Inorganic Chemistry
Topics & keywords
- Chemistry
- Indazole
- Mode of action
- Drug
- Pharmacology
- Drug development
- Cancer research
- Medicine
- Good health and well-being